In:
eLife, eLife Sciences Publications, Ltd, Vol. 7 ( 2018-05-15)
Abstract:
Trillions of microbes live within the human gut and influence our health. In particular, these microbes can modify food and drugs into compounds (metabolites) that humans cannot produce on their own. These compounds are often beneficial to the human host, but in some cases – for example, if the modification alters how a drug works – can be detrimental. Digoxin is a toxic chemical produced by plants that, in low doses, can be used to treat heart conditions. It has been known for decades that the human gut bacterium Eggerthella lenta transforms digoxin into a metabolite that is an ineffective drug. Microbes use biological catalysts called enzymes to produce metabolites, but it was not known which enzymes enable E. lenta to modify digoxin. Using biochemical and genomic techniques, Koppel et al. now show that an enzyme called Cgr2 inactivates digoxin and other related plant toxins. Data about the gut microbes in nearly 1,900 people from three continents revealed that bacteria that can produce Cgr2 were present in the guts of more than 40% of the individuals, although often in low abundance. Further experiments did not reveal any obvious benefits that E. lenta gains from modifying digoxin. Instead, Koppel et al. propose that the bacteria carry out this modification to protect their human host from plant toxins. The results presented by Koppel et al. emphasise that the activities of gut microbes should be considered when designing new drugs or assessing how they work in the human body. The strategies used to identify Cgr2 could now be applied to discover other important gut microbe-drug interactions. Ultimately, this knowledge will help us to predict and control the activities of gut microbes in ways that could improve human health.
Type of Medium:
Online Resource
ISSN:
2050-084X
DOI:
10.7554/eLife.33953.001
DOI:
10.7554/eLife.33953.002
DOI:
10.7554/eLife.33953.003
DOI:
10.7554/eLife.33953.004
DOI:
10.7554/eLife.33953.005
DOI:
10.7554/eLife.33953.006
DOI:
10.7554/eLife.33953.007
DOI:
10.7554/eLife.33953.011
DOI:
10.7554/eLife.33953.012
DOI:
10.7554/eLife.33953.013
DOI:
10.7554/eLife.33953.014
DOI:
10.7554/eLife.33953.015
DOI:
10.7554/eLife.33953.008
DOI:
10.7554/eLife.33953.009
DOI:
10.7554/eLife.33953.010
DOI:
10.7554/eLife.33953.016
DOI:
10.7554/eLife.33953.017
DOI:
10.7554/eLife.33953.019
DOI:
10.7554/eLife.33953.020
DOI:
10.7554/eLife.33953.021
DOI:
10.7554/eLife.33953.018
DOI:
10.7554/eLife.33953.022
DOI:
10.7554/eLife.33953.025
DOI:
10.7554/eLife.33953.023
DOI:
10.7554/eLife.33953.024
DOI:
10.7554/eLife.33953.026
DOI:
10.7554/eLife.33953.031
DOI:
10.7554/eLife.33953.027
DOI:
10.7554/eLife.33953.028
DOI:
10.7554/eLife.33953.029
DOI:
10.7554/eLife.33953.030
DOI:
10.7554/eLife.33953.032
DOI:
10.7554/eLife.33953.033
DOI:
10.7554/eLife.33953.034
DOI:
10.7554/eLife.33953.035
DOI:
10.7554/eLife.33953.036
DOI:
10.7554/eLife.33953.037
DOI:
10.7554/eLife.33953.038
DOI:
10.7554/eLife.33953.043
DOI:
10.7554/eLife.33953.044
DOI:
10.7554/eLife.33953.040
DOI:
10.7554/eLife.33953.041
DOI:
10.7554/eLife.33953.042
Language:
English
Publisher:
eLife Sciences Publications, Ltd
Publication Date:
2018
detail.hit.zdb_id:
2687154-3
Bookmarklink